EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, TNXP:

19 Sep 2025
LAST:

26.00

CHANGE:
 2.37		OPEN:
28.37		HIGH:
28.42		ASK:
4.35		VOLUME:
1.86M
CHG(%):
8.35		PREV:
28.37		LOW:
25.97		BID:
2.80		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Sep 2526.2126.2126.1926.19300
19 Sep 2528.3728.4225.9726.001.86M
18 Sep 2527.8128.9627.7328.371.3M
17 Sep 2527.0129.1926.8927.711.46M
16 Sep 2527.7728.6027.1127.121.12M
15 Sep 2529.0029.0026.3727.751.11M
12 Sep 2530.5131.2828.5128.61685K
11 Sep 2527.1331.5526.8631.211.37M
10 Sep 2526.5227.5925.2826.991.79M
09 Sep 2525.0025.8424.2025.821.34M

COMPANY PROFILE

Name:Tonix Pharm Holdings
About:Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:26 Main Street, Chatham, NJ, United States, 07928
Website:https://www.tonixpharma.com
CUSIP:890260102
CIK:0001430306
ISIN:US8902608392
FIGI:BBG000LG8XM5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:0.01
Price to Book:1.91
Price to Sales:32.57
Shares:8.77M
Market Cap:227.91M

TECHNICAL INDICATORS

MA5:27.39
MA10:27.49
MA20:29.11
MA50:38.83
MA100:35.32
MA200:22.26
STO9:3.14
STO14:11.34
RSI14:40.19
WPR14:-88.01
MTM14:-1.66
ROC14:-0.06
ATR:2.32
Week High:31.28
Week Low:25.97
Month High:39.45
Month Low:24.20
Year High:69.97
Year Low:0.12
Volatility:54.34

RECENT SPLITS

Date Ratio
05 Feb 20251-100
10 Jun 20241-32
10 May 202316-100
17 May 20221-32
01 Nov 20191-10
28 Nov 20181-10
17 Mar 20171-10
01 May 20131-20